TERESA GILLILAND: Open Payments
NPI 1255799540 · SALISBURY, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$781 in 28 payments from 9 companies in 2025. Trend: 2023 $1,260 · 2024 $1,327 · 2025 $781
Food & beverage: $723Education: $57
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 9 | $311 |
| CSL Behring | 9 | $186 |
| GENZYME CORPORATION | 1 | $74 |
| SANOFI-AVENTIS U.S. LLC | 1 | $57 |
| BioCryst US Sales Co., LLC | 2 | $45 |
| Novartis Pharmaceuticals Corporation | 2 | $40 |
| Amgen Inc. | 2 | $34 |
| Grifols USA, LLC | 1 | $18 |
| Paratek Pharmaceuticals, Inc. | 1 | $16 |
Products named: FASENRA, Hizentra, WAYRILZ, TEZSPIRE, DUPIXENT, Andembry, ORLADEYO, Rhapsido.
Industry payments across MD — which companies pay providers there.
